The suppression of RASD1 partially reverses the tumor-promoting impacts of KIAA1429, thereby underscoring its clinical significance as a prognostic biomarker and a prospective therapeutic target in the realm of gastric cancer [73]. This evidence concerns the gene VIRMA and neoplasm.